Patents by Inventor Bridget Puffer
Bridget Puffer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230235033Abstract: The disclosure provides engineered polypeptides that specifically bind to human complement component C5 and/or serum albumin. The disclosure also provides fusion proteins comprising such engineered polypeptides, wherein such fusion proteins may be multivalent and multi-specific fusion proteins. The disclosure further provides nucleic acid molecules that encode such engineered polypeptides or fusion proteins, and methods of making such engineered polypeptides or fusion proteins. The disclosure further provides pharmaceutical compositions that comprise such engineered polypeptides or fusion proteins, and methods of treatment using such engineered polypeptides or fusion proteins.Type: ApplicationFiled: October 7, 2022Publication date: July 27, 2023Inventors: Bridget PUFFER, Julian CHANDLER, Nimish GERA, Douglas L. SHERIDAN, Siddharth JINDAL, Paul P. TAMBURINI
-
Patent number: 11498960Abstract: The disclosure provides engineered polypeptides that specifically bind to human complement component C5 and/or serum albumin. The disclosure also provides fusion proteins comprising such engineered polypeptides, wherein such fusion proteins may be multivalent and multi-specific fusion proteins. The disclosure further provides nucleic acid molecules that encode such engineered polypeptides or fusion proteins, and methods of making such engineered polypeptides or fusion proteins. The disclosure further provides pharmaceutical compositions that comprise such engineered polypeptides or fusion proteins, and methods of treatment using such engineered polypeptides or fusion proteins.Type: GrantFiled: July 11, 2018Date of Patent: November 15, 2022Assignee: Alexion Pharmaceuticals, Inc.Inventors: Bridget Puffer, Julian Chandler, Nimish Gera, Douglas L. Sheridan, Siddharth Jindal, Paul P. Tamburini
-
Publication number: 20200399351Abstract: The disclosure provides engineered polypeptides that specifically bind to human complement component C5 and/or serum albumin. The disclosure also provides fusion proteins comprising such engineered polypeptides, wherein such fusion proteins may be multivalent and multi-specific fusion proteins. The disclosure further provides nucleic acid molecules that encode such engineered polypeptides or fusion proteins, and methods of making such engineered polypeptides or fusion proteins. The disclosure further provides pharmaceutical compositions that comprise such engineered polypeptides or fusion proteins, and methods of treatment using such engineered polypeptides or fusion proteins.Type: ApplicationFiled: July 11, 2018Publication date: December 24, 2020Inventors: Bridget PUFFER, Julian CHANDLER, Nimish GERA, Douglas L. SHERIDAN, Siddharth JINDAL, Paul P. TAMBURINI
-
Publication number: 20160168237Abstract: The present disclosure relates to, inter alia, a method of treating a complement mediated disorder caused by an infectious agents in a patient, comprising administering an effective amount of a C5 inhibitor, such as eculizumab or an eculizumab variant, to the patient.Type: ApplicationFiled: December 11, 2015Publication date: June 16, 2016Inventors: Darrell Fontenot, Bridget Puffer, Bruce Andrien, Mittie Doyle, Paul Tamburini, Camille Bedrosian
-
Patent number: 8691961Abstract: The present invention relates to the production and uses of flavivirus replicons and flavivirus particles and reporter virus particles. The present invention relates to the production and uses of chimeric and codon-optimized flavivirus virus replicons and flavivirus virus particles and reporter virus particles.Type: GrantFiled: November 9, 2010Date of Patent: April 8, 2014Assignee: Integral Molecular, Inc.Inventors: Bridget Puffer, Kimberly-Anne Mattia
-
Publication number: 20080318208Abstract: The present invention relates to the production and uses of Dengue virus replicons and Dengue reporter virus particles. The present invention relates to methods of identifying inhibitors of Dengue virus infection, inhibitors of Dengue virus replication, and inhibitors of Dengue virus assembly.Type: ApplicationFiled: February 12, 2007Publication date: December 25, 2008Applicant: Integral Molecular, Inc.Inventors: Bridget Puffer, Benjamin J. Doranz
-
Patent number: 7026113Abstract: The invention provides an equine infectious anemia (EIA) vaccine that provides immunity to mammals, especially equines, from infection with equine infectious anemia virus (EIAV) and which allows differentiation between vaccinated and non-vaccinated, but exposed, mammals or equines. Preferably said vaccine encompasses at least one mutation in an EIAV which produces a non-functional gene in the vaccine virus that is always expressed in disease-producing wild-type EIA viruses. Additionally, said EIA vaccine virus cannot cause clinical disease in mammals or spread or shed to other mammals including equines.Type: GrantFiled: June 26, 2002Date of Patent: April 11, 2006Assignee: Akzo Nobel N.V.Inventors: Ronald Montelaro, Bridget Puffer, Feng Li, Charles Issel, Kristina J. Hennessy, Karen K. Brown
-
Patent number: 6727078Abstract: Disclosed herein is a vaccine which provides immunity to mammals from infection and/or disease caused by a lentivirus, such as equine infectious anemia virus, human immunodeficiency virus (HIV), feline immunodeficiency virus (FIV), bovine immunodeficiency virus (BIV) or simian immunodeficiency virus (SIV) said composition comprising a deletion in a gene that blocks replication of the virus in vivo. Preferably said composition encompasses at least one deletion in a lentivirus which provides protection from exposure to wild-type lentiviruses. It also encompasses a marker vaccine in which a foreign gene is inserted into the gene-deleted region, said inserted gene providing a diagnostic tool for use in vaccinated mammals. The scope of the invention encompasses an EIAV vaccine that allows equines to be safely vaccinated and protected from disease without converting to a seropositive status on the Coggin's Test or any other test wich measures p26.Type: GrantFiled: April 18, 2002Date of Patent: April 27, 2004Assignees: Akzo Nobel N.V., University of Pittsburgh of the Commonwealth System of Higher EducationInventors: Ronald Montelaro, Jodi Craigo, Charles Issel, Bridget Puffer, Kristina J. Hennessey, Karen K. Brown
-
Publication number: 20040018211Abstract: The invention provides an equine infectious anemia (EIA) vaccine that provides immunity to mammals, especially equines, from infection with equine infectious anemia virus (EIAV) and which allows differentiation between vaccinated and non-vaccinated, but exposed, mammals or equines. Preferably said vaccine encompasses at least one mutation in an EIAV which produces a non-functional gene in the vaccine virus that is always expressed in disease-producing wild-type EIA viruses. Additionally, said EIA vaccine virus cannot cause clinical disease in mammals or spread or shed to other mammals including equines.Type: ApplicationFiled: February 19, 2003Publication date: January 29, 2004Inventors: Ronald Montelaro, Bridget Puffer, Feng Li, Charles Issel, Kristina J. Hennessy, Karen K. Brown
-
Publication number: 20030170272Abstract: The invention provides an equine infectious anemia (EIA) vaccine that provides immunity to mammals, especially equines, from infection with equine infectious anemia virus (EIAV) and which allows differentiation between vaccinated and non-vaccinated, but exposed, mammals or equines. Preferably said vaccine encompasses at least one mutation in an EIAV which produces a non-functional gene in the vaccine virus that is always expressed in disease-producing wild-type EIA viruses. Additionally, said EIA vaccine virus cannot cause clinical disease in mammals or spread or shed to other mammals including equines.Type: ApplicationFiled: April 7, 2003Publication date: September 11, 2003Inventors: Ronald Montelaro, Bridget Puffer, Feng Li, Charles Issel, Kristina J. Hennessy, Karen K. Brown
-
Publication number: 20030165536Abstract: The invention provides an equine infectious anemia (EIA) vaccine that provides immunity to mammals, especially equines, from infection with equine infectious anemia virus (EIAV) and which allows differentiation between vaccinated and non-vaccinated, but exposed, mammals or equines. Preferably said vaccine encompasses at least one mutation in an EIAV which produces a non-functional gene in the vaccine virus that is always expressed in disease-producing wild-type EIA viruses. Additionally, said EIA vaccine virus cannot cause clinical disease in mammals or spread or shed to other mammals including equines.Type: ApplicationFiled: June 26, 2002Publication date: September 4, 2003Inventors: Ronald Montelaro, Bridget Puffer, Feng Li, Charles Issel, Kristina J. Hennessy, Karen K. Brown
-
Patent number: 6585978Abstract: The invention provides an equine infectious anemia (EIA) vaccine that provides immunity to mammals, especially equines, from infection with equine infectious anemia virus (EIAV) and which allows differentiation between vaccinated and non-vaccinated, but exposed, mammals or equines. Preferably said vaccine encompasses at least one mutation in an EIAV which produces a non-functional gene in the vaccine virus that is always expressed in disease-producing wild-type EIA viruses. Additionally, said EIA vaccine virus cannot cause clinical disease in mammals or spread or shed to other mammals including equines.Type: GrantFiled: September 9, 2000Date of Patent: July 1, 2003Assignee: Akzo NobelInventors: Ronald Montelaro, Bridget Puffer, Feng Li, Charles Issel, Kristina J. Hennessy, Karen K. Brown
-
Patent number: 6528250Abstract: The invention relates to a method for infecting equines with an equine infectious anemia virus (EIAV) in order to reproduce a natural infection challenge model. More specifically, the invention provides a multiple low dose equine EIA challenge model comprising administering at least 1 median horse infective dose to an equine using an intravenous route of administration. It is preferable that the EIAV be administered on a repeated basis. The multiple low dose EIA challenge model described herein can be used for testing efficacy of vaccines, treatments and diagnostic tests.Type: GrantFiled: September 9, 2000Date of Patent: March 4, 2003Assignee: Akzo Nobel N.V.Inventors: Ronald Montelaro, Bridget Puffer, Feng Li, Charles Issel, Kristina J. Hennessey, Karen K. Brown
-
Publication number: 20030026814Abstract: Disclosed herein is a vaccine which provides immunity to mammals from infection and/or disease caused by a lentivirus, such as equine infectious anemia virus, human immunodeficiency virus (HIV), feline immunodeficiency virus (FIV), bovine immunodeficiency virus (BIV) or simian immunodeficiency virus (SIV) said composition comprising a deletion in a gene that blocks replication of the virus in vivo. Said composition allows differentiation between vaccinated and non-vaccinated, but exposed, mammals and provides safety and immunity when administered as a vaccine to mammals. Preferably said composition encompasses at least one deletion in a lentivirus which allows mammals to be safely vaccinated and provides protection from exposure to wild-type lentiviruses. It also encompasses a marker vaccine in which a foreign gene is inserted into the gene-deleted region, said inserted gene providing a diagnostic tool for use in vaccinated mammals and, potentially, protection from infection from a foreign disease.Type: ApplicationFiled: April 18, 2002Publication date: February 6, 2003Inventors: Ronald Montelaro, Jodi Craigo, Charles Issel, Bridget Puffer, Kristina J. Hennessey, Karen K. Brown
-
Publication number: 20030021807Abstract: Disclosed herein is a vaccine which provides immunity to mammals from infection and/or disease caused by a lentivirus, such as equine infectious anemia virus, human immunodeficiency virus (HIV), feline immunodeficiency virus (FIV), bovine immunodeficiency virus (BIV) or simian immunodeficiency virus (SIV) said composition comprising a deletion in a gene that blocks replication of the virus in vivo. Said composition allows differentiation between vaccinated and non-vaccinated, but exposed, mammals and provides safety and immunity when administered as a vaccine to mammals. Preferably said composition encompasses at least one deletion in a lentivirus which allows mammals to be safely vaccinated and provides protection from exposure to wild-type lentiviruses. It also encompasses a marker vaccine in which a foreign gene is inserted into the gene-deleted region, said inserted gene providing a diagnostic tool for use in vaccinated mammals and, potentially, protection from infection from a foreign disease.Type: ApplicationFiled: June 24, 2002Publication date: January 30, 2003Inventors: Ronald Montelaro, Jodi Craigo, Charles Issel, Bridget Puffer, Kristina J. Hennessy, Karen K. Brown
-
Publication number: 20020155130Abstract: Disclosed herein is a vaccine which provides immunity to mammals from infection and/or disease caused by a lentivirus, such as equine infectious anemia virus, human immunodeficiency virus (HIV), feline immunodeficiency virus (FIV), bovine immunodeficiency virus (BIV) or simian immunodeficiency virus (SIV) said composition comprising a deletion in a gene that blocks replication of the virus in vivo. Said composition allows differentiation between vaccinated and non-vaccinated, but exposed, mammals and provides safety and immunity when administered as a vaccine to mammals. Preferably said composition encompasses at least one deletion in a lentivirus which allows mammals to be safely vaccinated and provides protection from exposure to wild-type lentiviruses. It also encompasses a marker vaccine in which a foreign gene is inserted into the gene-deleted region, said inserted gene providing a diagnostic tool for use in vaccinated mammals and, potentially, protection from infection from a foreign disease.Type: ApplicationFiled: April 18, 2002Publication date: October 24, 2002Inventors: Ronald Montelaro, Jodi Craigo, Charles Issel, Bridget Puffer, Kristina J. Hennessey, Karen K. Brown
-
Patent number: 6461616Abstract: Disclosed herein is a vaccine which provides immunity to mammals from infection and/or disease caused by a lentivirus, such as equine infectious anemia virus, human immunodeficiency virus (HIV), feline immunodeficiency virus (FIV), bovine immunodeficiency virus (BIV) or simian immunodeficiency virus (SIV) said composition comprising a deletion in a gene that blocks replication of the virus in vivo. Preferably said composition encompasses at least one deletion in a lentivirus which provides protection from exposure to wild-type lentiviruses. It also encompasses a marker vaccine in which a foreign gene is inserted into the gene-deleted region, said inserted gene providing a diagnostic tool for use in vaccinated mammals. The scope of the invention encompasses an EIAV vaccine that allows equines to be safely vaccinated and protected from disease without converting to a seropositive status on the Coggin's Test or any other test which measures p26.Type: GrantFiled: September 9, 2000Date of Patent: October 8, 2002Assignee: Akzo Nobel NVInventors: Ronald Montelaro, Jodi Craigo, Charles Issel, Bridget Puffer, Kristina J. Hennessy, Karen K Brown